Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s disease

McIntosh, E. et al. (2021) Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s disease. Movement Disorders, 36(9), pp. 2136-2143. (doi: 10.1002/mds.28623) (PMID:33960511)

[img] Text
238263.pdf - Published Version
Available under License Creative Commons Attribution.

272kB

Abstract

Background: The PD MED study reported small but persistent benefits in patient‐rated mobility scores and quality of life from initiating therapy with levodopa compared with levodopa‐sparing therapies in early Parkinson's disease (PD). Objectives: The objective was to estimate the cost‐effectiveness of levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors compared with levodopa alone. Methods: PD MED is a pragmatic, open‐label randomized, controlled trial in which patients newly diagnosed with PD were randomly assigned between levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors ) and levodopa alone. Mean quality‐adjusted life‐years and costs were calculated for each participant. Differences in mean quality‐adjusted life‐years and costs between levodopa and levodopa‐sparing therapies and between dopamine agonists and monoamine oxidase type B inhibitors were estimated using linear regression. Results: Over a mean observation period of 4 years, levodopa was associated with significantly higher quality‐adjusted life‐years (difference, 0.18; 95% CI, 0.05–0.30; P < 0.01) and lower mean costs (£3390; £2671–£4109; P < 0.01) than levodopa‐sparing therapies, the difference in costs driven by the higher costs of levodopa‐sparing therapies. There were no significant differences in the costs of inpatient, social care, and institutional care between arms. There was no significant difference in quality‐adjusted life‐years between those allocated dopamine agonists and monoamine oxidase type B inhibitors (0.02; −0.17 to 0.13 in favor of dopamine agonists; P = 0.81); however costs were significantly lower for those allocated monoamine oxidase type B inhibitors (£2321; £1628–£3015; P < 0.01) because of the higher costs of dopamine agonists. There were no significant differences between arms for other costs. Conclusions: Initial treatment with levodopa is highly cost‐effective compared with levodopa‐sparing therapies. Monoamine oxidase type B inhibitors, as initial levodopa‐sparing therapy was more cost‐effective, with similar quality‐adjusted life‐years but lower costs than dopamine agonists.

Item Type:Articles
Additional Information:Research Funding: UK NIHR HTA. Grant Number: ISRCT No: 69812316.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McIntosh, Professor Emma and Kent, Mr Seamus
Authors: McIntosh, E., Kent, S., Gray, A., Clarke, C. E., Williams, A., Jenkinson, C., Ives, N., Patel, S., Rick, C., Wheatley, K., and Gray, R.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Movement Disorders
Publisher:Wiley
ISSN:0885-3185
ISSN (Online):1531-8257
Published Online:07 May 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in Movement Disorders 36(9): 2136-2143
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record